Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich
zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
A New Standard Treatment for Older Individuals with Hodgkin Lymphoma
Patients over 60 with classic Hodgkin lymphoma (cHL) have worse treatment responses and outcomes than younger patients due to comorbidities, poor tolerance of therapy, and differences in HL biology. In the S1826 study, investigators assessed 6 cycles of the immune checkpoint inhibitor nivolumab (N) plus AVD (doxorubicin, vinblastine, and dacarbazine) versus brentuximab vedotin (BV) plus AVD in previously untreated patients with advanced-stage cHL and stratified by age group.
Key findings for participants aged ≥60 years:
- Two-year progression-free survival was significantly better for N-AVD (89%) than BV-AVD (64%); 2-year overall survival was 96% vs. 85%.
- Adverse events (including peripheral neuropathy) were more common with BV-AVD, and dose reductions were not necessary in 26% (BV-AVD) vs. 69% (N-AVD) of participants.
- Progression or relapse occurred in 8% (N-AVD) vs. 18% (BV-AVD) of patients; non-relapse mortality was 6% vs. 16%.
Comment
In representing a new standard of care for older patients with advanced-stage HL who are candidates for anthracycline-based combination chemotherapy, N-AVD has been adopted for use in our Cancer Center. We can attribute the encouraging outcomes in this study to the more-favorable dose intensity achieved with N-AVD, as well as the markedly improved responses in patients with EBV-positive HL who receive nivolumab.
Citation(s)
Author:
Rutherford SC et al.
Title:
Nivolumab-AVD versus brentuximab vedotin–AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826.
Source:
J Clin Oncol
2025
Jun
16; [e-pub].
(Abstract/FREE Full Text)
Empfohlen von
Michael E. Williams, MD, ScM